retatrutide and joint pain Reduces Body Weight by Nearly 30% in Phase 3 TRIUMPH-1 Trial, With Gains for Sleep Apnea Knee What Is Retatrutide And How
Description
GLP-1 receptor agonists (GLP-1 RAs), already established in the management of type 2 diabetes mellitus and obesity, have emerged as promising candidates for the treatment of nonalcoholic steatohepatitis (NASH), owing to their broad metabolic and hepatoprotective effects
Safety profiles across both studies mirrored other GLP-1 medications, with gastrointestinal side effects predominating
doi: 10.3389/fendo.2022.1043789 108 WhartonSDaviesMDickerDLingvayIMosenzonORubinoDMet al
Reporting Side Effects Through the MHRA Yellow Card Scheme Suspected side effects from retatrutide used outside a clinical trial should be reported via the MHRA Yellow Card Scheme
To put that in context, 30% body weight loss is the threshold historically associated with bariatric (weight-loss) surgery
Your resting metabolic rate drops, meaning your body burns fewer calories at rest, which makes it even harder to maintain weight loss long-term
